Background: Studies on the effectiveness of multimodal analgesia, particularly in patients at higher perioperative risk from obstructive sleep apnoea (OSA), are lacking. We aimed to assess the impact of multimodal analgesia on opioid use and complications in this high-risk cohort. Methods: We conducted a population-based retrospective cohort study of OSA patients undergoing elective lower extremity joint arthroplasty (2006e16, Premier Healthcare database). Multimodal analgesia was defined as opioid use with the addition of one, two, or more non-opioid analgesic modes including, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 inhibitors, paracetamol/acetaminophen, peripheral nerve blocks, steroids, gabapentin/pregabalin, or ketamine. Multilevel multivariable regression models measured associations between multimodal analgesia and opioid prescription (primary outcome; oral morphine equivalents). Secondary outcomes included opioid-and OSA-related complications, and resource utilisation. Odds ratios (OR) or % change and 95% confidence intervals (CI) are reported. Results: Among 181 182 OSA patients included, 88.5% (n ¼ 160 299) received multimodal analgesia with increasing utilisation trends. Multivariable models showed stepwise beneficial postoperative outcome effects with increasing additional analgesic modes compared with opioid-only analgesia. In patients who received more than two additional analgesia modes (n ¼ 64 174), opioid dose prescription decreased by 14.9% (CI À17.0%; À12.7%), while odds were significantly decreased for gastrointestinal complications (OR 0.65, CI 0.53; 0.78), mechanical ventilation (OR 0.23, CI 0.16; 0.32), and critical care admission (OR 0.60, CI 0.48; 0.75), all P<0.0001.
Obstructive sleep apnoea may increase the risk of perioperative complications, but the impact of multimodal analgesia on this is unknown. In this large retrospective cohort study of patients with obstructive sleep apnoea undergoing lower limb joint arthroplasty, most received some form of multimodal analgesia. Use of multimodal analgesia is associated with reduced perioperative complications and opioid use, with the greatest benefit coming from increasing analgesic modes.
Given the prospect of improved postoperative pain control and reduced opioid consumption, multimodal analgesia seems particularly appealing in patients at higher perioperative risk because of conditions such as obstructive sleep apnoea (OSA). Sedative and opioid-based medications account for a major concern in OSA, 1 as these drug categories interfere with respiratory drive and alertness. 2e4 Thus, current perioperative OSA recommendations include multimodal analgesia. 5 A recent study demonstrated incremental benefits with the use of additional analgesic modes in joint replacement surgery. 6 Nevertheless, evidence on a population level to assess benefits of this practice in patients at higher perioperative risk because of OSA is largely lacking. We therefore investigated the effectiveness of multimodal analgesia among patients with OSA undergoing lower extremity joint arthroplasty surgery. We analysed associations between multimodal analgesia and opioid use, opioid-related side-effects, OSA characteristic adverse outcomes, and resource utilisation. We hypothesised that the addition of non-opioid analgesic modes to opioid analgesia is associated with a reduction in opioid consumption and complications.
Methods

Study design and data source
In this population-based retrospective cohort study, we extracted data (from January 2006 to December 2016) from the Premier Healthcare Database 7 (Premier Healthcare Solutions, Inc., Charlotte, NC, USA), a national claims-based database with patient-specific inpatient billing information covering approximately 25% of US hospitals. Diagnoses and services provided were determined through International Classification of Diseases, Ninth Revision, Clinical Modification codes (ICD-9-CM, US health system's adaption of the international ICD-9 standard), Current Procedural Terminology codes, and standardised billing items. Approval was obtained by the Institutional Review Boards of the Hospital for Special Surgery (New York, NY, USA; #2012-050-CR2) and Icahn School of Medicine (New York, NY, USA; #14-00647). This study was exempt from requirements for consent, as data are deidentified and compliant with the Health Insurance Portability and Accountability Act.
Analysis plan
The analysis plan was established at the onset of the study (before data access) to define the population and intervention of interest, baseline variables of significance, and healthcare outcomes of importance in OSA patients.
Participants
We included patient records with a diagnosis of OSA who underwent elective, primary total hip arthroplasty (THA) or total knee arthroplasty (TKA); ICD-9-CM codes 81.51 and 81.54, respectively. ICD-9-CM definitions for the presence of OSA, comorbidities, and complications are presented in Appendix  Tables 3e5.   8 Variables
Baseline characteristics
According to the pre-specified analysis plan, the following baseline characteristics were investigated. Patient-related variables included age, gender, race (white, black, other) and insurance type (commercial, Medicaid, Medicare, uninsured, other). Hospital-related variables included, location (urban rural), size (<300, 300e499, !500 beds), teaching status, and number of annual hip/knee arthroplasties. Procedure-related variables included, year of procedure, use of general or neuraxial anaesthesia, and use of patient-controlled analgesia (PCA). The comorbidity burden was assessed using the Quan adaptation of the Charlson-Deyo Comorbidity Index. 9 Variables describing history of substance use/abuse, 10e12 chronic pain conditions, 13 and psychiatric conditions 12 were included as possible drivers of perioperative outcome, particularly through their correlation with opioid utilisation.
Exposure
The exposure of interest was the use of multimodal analgesia, while the comparator was the utilisation of opioid-only analgesia. Multimodal analgesia was defined as opioid analgesia plus the addition of non-opioid analgesic modes on the day of surgery or the day after, and categorised into the addition of one, two, or more than two non-opioid analgesic modes. Non-opioid analgesic modes included, peripheral nerve blocks, paracetamol/ acetaminophen, steroids, gabapentin/pregabalin, ketamine, NSAIDs, or cyclooxygenase-2 (COX-2) inhibitors, administered on the day of surgery or the day thereafter.
Outcomes
The primary outcome was inpatient opioid prescription dose (extracted from billing); this was analysed separately as opioid prescription during the entire hospital stay, and by hospitalisation day (day of surgery, postoperative Day 1, and inpatient days thereafter). Secondary outcomes were comprised of three categories. Adverse effects commonly attributed to opioids as previously established by Kessler and colleagues 14 included respiratory, gastrointestinal, genitourinary, CNS and 'other complications' (composite of ICD-9 codes for postoperative bradycardia, rash or itching, drugs causing adverse effects with therapeutic use, and fall from bed). Postoperative outcomes characteristic for the OSA population included CPAP use, mechanical ventilation, and the utilisation of critical care services. Lastly, outcomes reflecting the typically increased utilisation of resources in OSA, included cost and length of stay (LOS). 15 Inpatient opioid prescription was expressed in oral morphine equivalents, calculated by converting inpatient opioid charges using the Lexicomp® 'opioid agonist conversion' 16 and the GlobalRPH 'opioid analgesic converter' 17 Cost of hospitalisation was adjusted for inflation and expressed in 2016 US dollars.
Study size
Exclusion criteria included non-elective procedures, unknown gender, unknown discharge status, outpatient procedures, cases in hospitals with <30 primary lower extremity joint replacements (to ensure sufficient sample size per cluster 18 ), no OSA diagnosis, absent billing for perioperative opioids (this may reflect missing data on opioids more than purposeful omission of opioid use, which is rare), and opioid prescription greater than the 95th percentile to exclude outliers. Figure 1 depicts the patient flow chart.
Statistical analysis
Univariable associations between the number of modes used and study variables, and outcomes were analysed using the c 2 test for categorical and the Kruskal-Wallis test for continuous variables. Multilevel, multivariable regression models (logistic and linear regression for binary and continuous outcomes, respectively) measured the association between multimodal analgesia categories (compared with opioids only) and outcomes. On the hospital level, models controlled for the correlation of patients within hospitals and fit separate regression lines by hospital, 19 because patients within the same hospital may be correlated, because of similarities in treatment care. Furthermore, within the multilevel model, we controlled for hospital-related variables. On the patient level, multivariable regression models were adjusted for all patient-related variables, insurance type, procedure-related variables, Charlson-Deyo Comorbidity index, history of substance use/abuse, chronic pain conditions, and psychiatric conditions. As parsimony is less of an issue when dealing with larger datasets, in practice our strategy ended up including all available covariates in the multivariable models. Adjusted odds ratios (OR) and Bonferroni-adjusted 95% confidence intervals (CI) were reported taking into account the number of hypotheses tested for in the main analyses (42 hypotheses; 14 outcomes, and three multimodal comparisons). Based on our sample size of 181 182 patients, our model achieves 100% power to detect a 5% decrease in opioid utilisation using a two-sided test with an alpha of 0.05 (under the conservative assumption that a 5% reduction in opioid utilisation would be the minimal reduction needed to be translated into differences in outcomes). It must be noted that while this step may reduce the risk of type I errors, the likelihood of type II errors may be increased. 20 For all models, the PROC GLIMMIX procedure in SAS version 9.4 statistical software (SAS Institute, Cary, NC, USA) was used; for opioid prescription, LOS, and cost of hospitalisation the gamma distribution with a log link function was applied as these variables are skewed. 21, 22 Effect estimates for these continuous outcomes are reported as % change and CI. Additionally, we used the CONTRAST statement in the SAS PROC GLIMMIX procedure to test whether a linear trend existed between effect estimates with increasing numbers of modes used in the multimodal analgesic approaches. 23 
Post hoc analyses
Several post hoc analyses were performed: first, to test the robustness of our results and the selected cohort, patients with opioid prescription above the 95th percentile were added to a sensitivity analysis (Appendix Tables 1 and 2 ). Moreover, we assessed the individual impact of each non-opioid analgesic mode (peripheral nerve blocks, paracetamol/acetaminophen, steroids, gabapentinoids, ketamine, NSAIDs, or COX-2 inhibitors) on opioid prescription dose. 
Results
Univariable analyses
Overall, 181 182 OSA patients undergoing joint arthroplasty (n¼48 475 THA; n¼132 707 TKA) were included. Multimodal analgesia was used in 88.5% (n¼160 299). Table 1 presents study variables by multimodal categorisation. Patients receiving multimodal analgesia were more likely to be white, on commercial insurance, in teaching hospitals, or in hospitals with higher arthroplasty volume.
The most commonly utilised non-opioid analgesics were paracetamol/acetaminophen (53.8%, n¼97 435/N¼181 182), NSAIDs (52.3%, n¼94 677/N¼181 182), COX-2 inhibitors (42.5%, n¼76 991/N¼181 182), and gabapentin/pregabalin (31.3%, n¼56 746/N¼181 182), followed by peripheral nerve blocks (15.2%, n¼27 482/N¼181 182), ketamine (5.7% n¼10 349/N¼181 182), and steroids (2.4%, n¼4359/N¼181 182).
One of the most pronounced differences between multimodal categories was the lower use of PCA in multimodal analgesia (26.6% in opioids only vs 19.2%, 13.7%, and 7.7% with increasing modes of multimodal analgesia, P<0.0001). The highest opioid dosage, LOS, cost, and rate of complications was observed in the 'opioids only' group. Figure 2 shows trends in the utilisation of multimodal analgesia by number of analgesic modes where particularly the group of patients receiving more than two non-opioid analgesic modes appear to be increasing. Figure 3 shows an overall decreasing trend in median annual per-procedure opioid dose prescription in each multimodal analgesia category.
Multivariable analyses
When analysing separate effects of non-opioid analgesic modes for multimodal analgesia, the strongest reduction in opioid prescription was associated with the use of COX-2 inhibitors [À12.6% (CI À14.0%; À11.1%)] and NSAIDs [À11.0% (CI À12.2%; À9.85%)] ( Table 2) . Tables 3 and 4 . With increasing modes of non-opioid analgesia in addition to opioids, a stepwise decrease in opioid prescription dose of up to À14.9% (CI À17.0%; À12.7%) was observed on postoperative Day 1, while LOS decreased by up to À11.8% (CI À13.0%; À10.7%) and minor decreases were observed for cost of hospitalisation, À3.2% (CI À4.2%; À2.2%).
With regards to associations between multimodal analgesia use and the occurrence of postoperative complications, the most pronounced estimates of effect were observed in reduced odds for postoperative mechanical ventilation (OR 0.23, CI 0.16; 0.32) and postoperative critical care admission (OR 0.60, CI 0.48; 0.75), which significantly decreased with the addition of two or more non-opioid analgesic modes. Notably, this was observed in a stepwise manner, in the context of a dose-response relationship. Similarly, a stepwise decrease in odds for gastrointestinal complications of up to 35% (OR 0.65, CI 0.53; 0.78) was found.
Sensitivity analysis
Sensitivity analysis, applying the same multivariable models in a cohort including patients with opioid prescription above the 95th percentile (n¼11 118) corroborated our initial findings. Notably, associations between multimodal analgesia and opioid prescription dose were more pronounced. Results are presented in Appendix Tables 1 and 2 .
Discussion
In this retrospective cohort analysis of 181 182 OSA patients undergoing major orthopaedic surgery, multimodal analgesia was utilised in 88.5% of the patients, with increasing use over time. With increasing numbers of non-opioid analgesic modes, a stepwise decrease in opioid prescription dose, resource utilisation, and odds for postoperative complications was observed. Notably, the strongest beneficial stepwise effect in the context of a dose-response gradient was observed in the association between multimodal analgesia and the significantly reduced need for postoperative mechanical ventilation and critical care admission. Analysis of individual multimodal analgesia components showed that COX-2 inhibitors and NSAIDs were associated with the strongest individual effect in opioid dose reduction. Although effect estimates appeared more modest for other analgesia modes, these may be augmented when various analgesic modes are utilised concurrently.
As a perioperative risk factor, OSA has particularly raised the level of concern for acute respiratory complications, 24, 25 potentially causing respiratory failure, requirement for critical care interventions, and possibly even death in the postoperative period.
26e28 Given its phenotype of chronic respiratory impairment with recurrent apnoea and hypopnoea, OSA by nature predisposes affected individuals to risks associated with anaesthetic medications and opioids in particular. The effects of these drugs can cause various degrees of airway collapse 1 and interact with consciousness, sleep, and respiratory drive. 2e4 Moreover, OSA has been linked to an increased risk for the presence of a difficult airway. 29, 30 This is important, as the postoperative period is crucial given the exacerbation in sleep disordered breathing 31 at a time of highest levels of pain and analgesic requirement. Chung and colleagues 31 demonstrated that cumulative 72-h opioid dose appears to independently drive a higher postoperative apnoea-hypopnoea index, while others have described possible alterations in pain sensitivity and augmented opioid potency in OSA. 32e34 Collectively, these factors have raised concerns among perioperative caregivers and spurred the release of recommendations on the use of risk-mitigating strategies including opioid dose reduction and safer analgesic pathways, such as multimodal analgesia. 5 Consistent with previous publications, 35, 36 the current analysis demonstrates that, with additional analgesic modes, a gradual decrease in opioid prescription dose is observed. However, the sheer reduction in utilised opioid dose does not per se establish a clinically meaningful benefit of multimodal analgesia unless its utilisation also results in reduced adverse events in the absence of adverse effects attributable to supplemental analgesic techniques. 37 To that extent, there is a lack of population-based studies investigating the impact of multimodal pain management on postoperative complications and resource utilisation, and potential harm reduction with the use of increasing numbers of pain management modalities. 35, 38 In this context, our study indeed shows beneficial reductions in complications. The odds for gastrointestinal complications significantly decreased in a stepwise manner by up to 35%, which mirrored a stepwise decrease in opioid prescription with increasing analgesic modalities used. However, the most consistent stepwise beneficial effects were observed for the need of postoperative mechanical ventilation and use of critical care services. These outcomes are of particular importance in OSA, because of the higher anticipated risk for life-threatening respiratory failure 24 and resource utilisation. 15, 27 The lack of increase in genitourinary complications throughout all multimodal categories should also be noted, in light of the fact that complementary use of drugs such as NSAIDs, COX-2 inhibitors, and paracetamol/acetaminophen, have been associated with their own risks, including renal toxicity. 29, 30 Notably, multimodal analgesia was also associated with a stepwise, continuous decrease in LOS by up to 11.8%, while a negligible effect was observed for cost of hospitalisation. The decrease in LOS, cost, and gastrointestinal complications with the use of multimodal analgesia could be related, given a recent population-based analysis in OSA patients demonstrating reduced odds for these complications at lower vs higher perioperative opioid dose concentrations. 39 Opioid dose-related side-effects, such as postoperative sedation, nausea and vomiting, urinary retention, and ileus may contribute to delayed hospital discharge at increased cost. 40, 41 However, the modest effect observed for cost may be reflective of the fact that in major surgeries with relatively short LOS, most resource utilisation (and thus costs) may be incurred on the day of the surgery. Thus, a longer LOS may not be proportionally linked to total cost of hospitalisation. An increasing body of evidence has suggested a potential impact of regional anaesthesia related procedures on postoperative outcomes. 42 This concept has increasingly been applied to patients at higher perioperative risk such as those with OSA. Consistent with our findings for multimodal analgesia, a recent population-based analysis in OSA patients similarly showed that the utilisation of regional vs general anaesthesia was associated with reduced odds for mechanical ventilation, critical care requirement, prolonged LOS, and increased cost. 43 
Limitations
A number of limitations, primarily attributable to the retrospective observational nature of this analysis, should be mentioned. Causality cannot be established, thus conclusions require cautious interpretation. Despite adjustments for numerous baseline characteristics (including substance abuse/ use, chronic pain, psychiatric comorbidities, and preoperative opioid use disorder to minimise the potential effect of preoperative opioid use), the lack of detailed clinical information (e.g. postoperative pain, local anaesthetic infiltration use, and OSA severity) in our dataset bears the risk for residual confounding, including indication or selection bias. However, we believe this risk has been minimised by comprehensive adjustments for baseline variables, by sensitivity analysis and given the doseresponse gradient observed in outcomes. This analysis relates to opioid prescription, rather than actual opioid consumption, because of the lack of such information in most large healthcare databases. Therefore, the observed effect of prescription dose reduction by multimodal analgesia could be underestimated, as patients may not have consumed all opioid prescriptions. Given the overflow of information on numerous combinations of multimodal analgesia, dose information could not be included. Our variable, however, reflects the intention to multimodal analgesia, thus is reflective of our main study interest. Although adjustment for enhanced recovery pathways was not possible, multimodal analgesia is a key component of these pathways, therefore our main exposure variable likely adjusted for this indirectly. ICD-9 coding of OSA bears its own limitations, given the variability in OSA assessment methods and disease severity. There has been one validation study, however, using Canadian data, which may not be reflective of the US, especially as coding practices may differ with varying financial incentives. 44, 45 The overall underestimation of true OSA burden because of the large proportion of undiagnosed OSA patients will apply to our dataset as well. Our findings may therefore only apply to those with diagnosed OSA (presumably those with the most complaints) and further research is needed on how multimodal strategies affect perioperative risk in the full scope of OSA patients. Finally, despite rigorous efforts by Premier to provide data review and validation, potential coding errors and inconsistencies cannot be fully excluded. Nevertheless, the stepwise nature of changes observed in outcomes, is in line with a dose-response relationship, a factor raising the quality of evidence. 46 Given the potential for significant improvement of perioperative safety in OSA, future research is needed to further spur the simultaneous utilisation of multiple non-opioid analgesia pathways. An increased use of multimodal analgesia seems particularly desirable in bariatric surgery, given the high OSA prevalence. 47 Moreover, besides opioid dose reduction, other analgesia related mechanisms, such as nerve blockade, may also significantly contribute to improved outcome. 48 In conclusion, the utilisation of an increasing number of non-opioid analgesic modes was associated with a significant, stepwise decrease in opioid prescription dose, resource utilisation, and postoperative complications in a group considered at high risk for perioperative complications because of OSA. The most pronounced effects were observed in the reduction of the need for mechanical ventilation and critical care admission. These findings were observed in the context of a dose-response relationship, a factor established to represent increased quality of evidence. Given the significant concern for critical respiratory failure in OSA, multimodal analgesia may present an effective strategy for perioperative risk reduction in this patient population.
